NKTX
HEALTHCARENkarta Inc
$3.32+0.24 (+7.79%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NKTX Today?
No stock-specific AI insight has been generated for NKTX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$1.63$3.65
$3.32
Fundamentals
Market Cap$237M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding71.3M
NKTX News
21 articles- NKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramYahoo Finance·Apr 17, 2026
- Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology CentersYahoo Finance·Apr 15, 2026
- Nkarta to Participate in Needham Virtual Healthcare ConferenceYahoo Finance·Apr 9, 2026
- Idiopathic Membranous Nephropathy Market is Predicted to Reach USD 1 Billion by 2036 Due to Rising Therapeutic Options | DelveInsightGlobeNewswire Inc.·Apr 6, 2026
- Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate HighlightsYahoo Finance·Mar 25, 2026
- CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsightYahoo Finance·Mar 10, 2026
- Nkarta to Participate in March Investor ConferencesYahoo Finance·Feb 27, 2026
- Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face LossesMotley Fool·Jan 21, 2026
- We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth CarefullyYahoo Finance·Dec 4, 2025
- Nkarta to Participate in Evercore Healthcare ConferenceYahoo Finance·Dec 2, 2025
- Nkarta Reports Third Quarter 2025 Financial Results and Corporate HighlightsYahoo Finance·Nov 10, 2025
- Nkarta to Participate in November Investor ConferencesYahoo Finance·Oct 30, 2025
- Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsightYahoo Finance·Oct 22, 2025
- Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence MeetingYahoo Finance·Oct 22, 2025
- Nkarta to Participate in a September Investor ConferenceYahoo Finance·Sep 2, 2025
- Nkarta Reports Second Quarter 2025 Financial Results and Corporate HighlightsYahoo Finance·Aug 12, 2025
- Nkarta to Participate in the H.C. Wainwright “HCW@Home” SeriesYahoo Finance·Jul 23, 2025
- Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?Yahoo Finance·Jun 27, 2025
- Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune FocusYahoo Finance·Jun 6, 2025
- Nkarta (NKTX) Moves to Buy: Rationale Behind the UpgradeYahoo Finance·May 19, 2025
- Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune SpaceYahoo Finance·May 15, 2025
All 21 articles loaded
Price Data
Open$2.81
Previous Close$3.08
Day High$3.02
Day Low$2.69
52 Week High$3.65
52 Week Low$1.63
52-Week Range
$1.63$3.65
$3.32
Fundamentals
Market Cap$237M
P/E Ratio—
EPS$-1.41
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin—
Debt / Equity—
Trading
Volume1.3M
Avg Volume (10D)—
Shares Outstanding71.3M
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and markets cell therapies for the treatment of cancer. The company is headquartered in South San Francisco, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—